While “good” adiponectin has antiatherosclerotic action and usually decreases with obesity, adiponectin tended be higher in patients receiving Theracurmin® when compared to those receiving placebo. The gene discussed is ADIPOQ; the disease is obesity due to melanocortin 4 receptor deficiency.